This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 964220. This website reflects only the author’s view and the Commission is not responsible for any use that may be made of the information it contains.

AI-Mind project clinical protocol recently published

AI-Mind kicks off the new year with excellent news. A new publication from the project partners titled: “Intelligent Digital Tools for Screening Brain Connectivity and Estimating Dementia Risk in Mild Cognitive Impairment: The AI-Mind Clinical Study Protocol” was recently published in Frontiers in Neurorobotics. Aligning with the European Commission’s Open Science policy, this insightful paper is available in full open access.

In close collaboration across diverse institutions and disciplines, the AI-Mind project introduces an innovative method for early risk assessment using advanced artificial intelligence (AI) on multimodal data. Project partners develop two AI-based tools integrated into the online platform. The AI-Mind Connector identifies dysfunctional brain networks through high-density magneto- and electroencephalography (M/EEG) recordings. Subsequently, the AI-Mind Predictor utilises data from the Connector, enriched with cognitive tests, genetic and protein biomarkers, sociodemographic, and clinical variables to predict an individual’s risk of developing dementia.


The AI-Mind protocol paper is a great milestone in our research journey. The many following publications from AI-Mind partners will be detail-orientated and will refer to the interdisciplinarity of the AI-Mind project. We are excited to assure the reader of a thrilling 2024 and 2025  year with new insights into the presymptomatic dementia identification of risk with the use of new biomarkers. – shares Dr Ira Haraldsen, the AI-Mind coordinator.

Leaders of the AI-Mind study from five clinical centres. 

The most recent publication delves into the clinical study protocol of AI-Mind, elucidating clinical, ethical, social, and technical challenges that the project addresses. Crucially, it lays the foundation for future scientific contributions by providing insights into the background of the AI-Mind study and the potential impact of the project on dementia risk assessment. Moving forward, the AI-Mind project plans to elaborate on various aspects outlined in the paper, encompassing M/EEG features, AI frameworks for AI-Mind data, data governance management, neuropsychological and cognitive considerations, health technology assessment (HTA), and ethical implications. The clinical study, as detailed in the publication, is expected to make significant contributions to ongoing discussions about the clinical assessment of AI-Mind across four European countries.


The AI-Mind project marks a significant milestone in leveraging AI to enhance early detection and intervention in dementia. It exemplifies collaborative efforts from experts across diverse fields, pushing the boundaries of neuroscience and artificial intelligence. The AI-Mind project also benefits from its integration into a network of major European initiatives, including The Virtual Brain, The Virtual Epileptic Patient, and EBRAINS AISBL service for sensitive data, HealthDataCloud.


Stay tuned for more updates as the AI-Mind project continues to advance dementia research and prevention.